{"pmid":32471655,"title":"Overwhelming COVID-19 Clinical Trials: Call for Prospective Meta-Analyses.","text":["Overwhelming COVID-19 Clinical Trials: Call for Prospective Meta-Analyses.","Trends Pharmacol Sci","Ma, Zhongren","Liu, Jiaye","Pan, Qiuwei","32471655"],"journal":"Trends Pharmacol Sci","authors":["Ma, Zhongren","Liu, Jiaye","Pan, Qiuwei"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32471655","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.tips.2020.05.002","keywords":["covid-19","clinical trial","prospective meta-analysis"],"weight":0,"_version_":1668255193354993664,"score":9.490897,"similar":[{"pmid":32108352,"title":"Clinical trial analysis of 2019-nCoV therapy registered in China.","text":["Clinical trial analysis of 2019-nCoV therapy registered in China.","So far, there is a lack of effective drugs for the new coronavirus pneumonia. With more and more patients diagnosed, China has carried out more than 100 clinical studies of new coronavirus infection, including antiviral drugs, antimalarial drugs, glucocorticoids, plasma therapy, virus vaccine, and other Western drugs, while Chinese medicine research accounted for half of the studies. Most of the trials were initiated by investigators and the study period would last for 1 to 11 months. The primary endpoints included symptom improvement and virus nucleic acid turning negative, but the optimal endpoint has not been determined. Although the final results of studies will take a long time to complete, the interim research data may provide some help for the current urgent demand for drug treatment. Compared with that of during SARS period in 2003, China has the stronger capability to carry out clinical trials of new drugs in emergency period.","J Med Virol","Zhang, Qi","Wang, Yakun","Qi, Changsong","Shen, Lin","Li, Jian","32108352"],"abstract":["So far, there is a lack of effective drugs for the new coronavirus pneumonia. With more and more patients diagnosed, China has carried out more than 100 clinical studies of new coronavirus infection, including antiviral drugs, antimalarial drugs, glucocorticoids, plasma therapy, virus vaccine, and other Western drugs, while Chinese medicine research accounted for half of the studies. Most of the trials were initiated by investigators and the study period would last for 1 to 11 months. The primary endpoints included symptom improvement and virus nucleic acid turning negative, but the optimal endpoint has not been determined. Although the final results of studies will take a long time to complete, the interim research data may provide some help for the current urgent demand for drug treatment. Compared with that of during SARS period in 2003, China has the stronger capability to carry out clinical trials of new drugs in emergency period."],"journal":"J Med Virol","authors":["Zhang, Qi","Wang, Yakun","Qi, Changsong","Shen, Lin","Li, Jian"],"date":"2020-02-29T11:00:00Z","year":2020,"_id":"32108352","source":"PubMed","week":"20209|Feb 24 - Mar 01","doi":"10.1002/jmv.25733","keywords":["china","clinical trial","new coronavirus pneumonia","new drugs"],"locations":["China","Chinese","China","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1666138492869017600,"score":52.669666},{"pmid":32205204,"pmcid":"PMC7102549","title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.","text":["Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.","BACKGROUND: Chloroquine and hydroxychloroquine have been found to be efficient on SARS-CoV-2, and reported to be efficient in Chinese COV-19 patients. We evaluate the role of hydroxychloroquine on respiratory viral loads. PATIENTS AND METHODS: French Confirmed COVID-19 patients were included in a single arm protocol from early March to March 16(th), to receive 600mg of hydroxychloroquine daily and their viral load in nasopharyngeal swabs was tested daily in a hospital setting. Depending on their clinical presentation, azithromycin was added to the treatment. Untreated patients from another center and cases refusing the protocol were included as negative controls. Presence and absence of virus at Day6-post inclusion was considered the end point. RESULTS: Six patients were asymptomatic, 22 had upper respiratory tract infection symptoms and eight had lower respiratory tract infection symptoms. Twenty cases were treated in this study and showed a significant reduction of the viral carriage at D6-post inclusion compared to controls, and much lower average carrying duration than reported of untreated patients in the literature. Azithromycin added to hydroxychloroquine was significantly more efficient for virus elimination. CONCLUSION: Despite its small sample size our survey shows that hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin.","Int J Antimicrob Agents","Gautret, Philippe","Lagier, Jean-Christophe","Parola, Philippe","Hoang, Van Thuan","Meddeb, Line","Mailhe, Morgane","Doudier, Barbara","Courjon, Johan","Giordanengo, Valerie","Vieira, Vera Esteves","Dupont, Herve Tissot","Honore, Stephane","Colson, Philippe","Chabriere, Eric","La Scola, Bernard","Rolain, Jean-Marc","Brouqui, Philippe","Raoult, Didier","32205204"],"abstract":["BACKGROUND: Chloroquine and hydroxychloroquine have been found to be efficient on SARS-CoV-2, and reported to be efficient in Chinese COV-19 patients. We evaluate the role of hydroxychloroquine on respiratory viral loads. PATIENTS AND METHODS: French Confirmed COVID-19 patients were included in a single arm protocol from early March to March 16(th), to receive 600mg of hydroxychloroquine daily and their viral load in nasopharyngeal swabs was tested daily in a hospital setting. Depending on their clinical presentation, azithromycin was added to the treatment. Untreated patients from another center and cases refusing the protocol were included as negative controls. Presence and absence of virus at Day6-post inclusion was considered the end point. RESULTS: Six patients were asymptomatic, 22 had upper respiratory tract infection symptoms and eight had lower respiratory tract infection symptoms. Twenty cases were treated in this study and showed a significant reduction of the viral carriage at D6-post inclusion compared to controls, and much lower average carrying duration than reported of untreated patients in the literature. Azithromycin added to hydroxychloroquine was significantly more efficient for virus elimination. CONCLUSION: Despite its small sample size our survey shows that hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin."],"journal":"Int J Antimicrob Agents","authors":["Gautret, Philippe","Lagier, Jean-Christophe","Parola, Philippe","Hoang, Van Thuan","Meddeb, Line","Mailhe, Morgane","Doudier, Barbara","Courjon, Johan","Giordanengo, Valerie","Vieira, Vera Esteves","Dupont, Herve Tissot","Honore, Stephane","Colson, Philippe","Chabriere, Eric","La Scola, Bernard","Rolain, Jean-Marc","Brouqui, Philippe","Raoult, Didier"],"date":"2020-03-25T11:00:00Z","year":2020,"_id":"32205204","source":"PubMed","week":"202013|Mar 23 - Mar 29","doi":"10.1016/j.ijantimicag.2020.105949","keywords":["2019-ncov","covid-19","sars-cov-2","azithomycin","clinical trial","hydroxychloroquine"],"locations":["French"],"countries":["France"],"countries_codes":["FRA|France"],"e_drugs":["Hydroxychloroquine","Chloroquine","Azithromycin"],"topics":["Treatment"],"weight":1,"_version_":1666138490185711618,"score":50.227997},{"pmid":32459832,"title":"Importance of Pediatric Inclusion in COVID-19 Therapeutic Trials.","text":["Importance of Pediatric Inclusion in COVID-19 Therapeutic Trials.","Pediatric patients are excluded from most COVID-19 therapeutic trials. We outline a rationale for the inclusion of children in COVID-19 therapeutic trials with enabled us to include children of all ages in a therapeutic COVID-19 trial at our institution.","Clin Infect Dis","Raabe, Vanessa N","Lighter, Jennifer","Caplan, Arthur L","Ratner, Adam J","32459832"],"abstract":["Pediatric patients are excluded from most COVID-19 therapeutic trials. We outline a rationale for the inclusion of children in COVID-19 therapeutic trials with enabled us to include children of all ages in a therapeutic COVID-19 trial at our institution."],"journal":"Clin Infect Dis","authors":["Raabe, Vanessa N","Lighter, Jennifer","Caplan, Arthur L","Ratner, Adam J"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32459832","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1093/cid/ciaa656","keywords":["covid-19","sars-cov-2","clinical trial","ethics","pediatrics"],"topics":["Treatment"],"weight":1,"_version_":1668141322625613825,"score":48.61222},{"pmid":32448345,"title":"Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.","text":["Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.","BACKGROUND: Coronavirus disease 2019 (COVID-19), caused by a novel corinavirus (later named SARS-CoV-2 virus), was fistly reported in Wuhan, Hubei Province, China towards the end of 2019. Large-scale spread within China and internationally led the World Health Organization to declare a Public Health Emergency of International Concern on 30(th) January 2020. The clinical manifestations of COVID-19 virus infection include asymptomatic infection, mild upper respiratory symptoms, severe viral pneumonia with respiratory failure, and even death. There are no antivirals of proven clinical efficacy in coronavirus infections. Remdesivir (GS-5734), a nucleoside analogue, has inhibitory effects on animal and human highly pathogenic coronaviruses, including MERS-CoV and SARS-CoV, in in vitro and in vivo experiments. It is also inhibitory against the COVID-19 virus in vitro. The aim of this study is to assess the efficacy and safety of remdesivir in adult patients with severe COVID-19. METHODS: The protocol is prepared in accordance with the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) guidelines. This is a phase 3, randomized, double-blind, placebo-controlled, multicentre trial. Adults (>/= 18 years) with laboratory-confirmed COVID-19 virus infection, severe pneumonia signs or symptoms, and radiologically confirmed severe pneumonia are randomly assigned in a 2:1 ratio to intravenously administered remdesivir or placebo for 10 days. The primary endpoint is time to clinical improvement (censored at day 28), defined as the time (in days) from randomization of study treatment (remdesivir or placebo) until a decline of two categories on a six-category ordinal scale of clinical status (1 = discharged; 6 = death) or live discharge from hospital. One interim analysis for efficacy and futility will be conducted once half of the total number of events required has been observed. DISCUSSION: This is the first randomized, placebo-controlled trial in COVID-19. Enrolment began in sites in Wuhan, Hubei Province, China on 6(th) February 2020. TRIAL REGISTRATION: ClinicalTrials.gov: NCT04257656. Registered on 6 February 2020.","Trials","Wang, Yeming","Zhou, Fei","Zhang, Dingyu","Zhao, Jianping","Du, Ronghui","Hu, Yi","Cheng, Zhenshun","Gao, Ling","Jin, Yang","Luo, Guangwei","Fu, Shouzhi","Lu, Qiaofa","Du, Guanhua","Wang, Ke","Lu, Yang","Fan, Guohui","Zhang, Yi","Liu, Ying","Ruan, Shunan","Liu, Wen","Jaki, Thomas","Hayden, Frederick G","Horby, Peter W","Cao, Bin","Wang, Chen","32448345"],"abstract":["BACKGROUND: Coronavirus disease 2019 (COVID-19), caused by a novel corinavirus (later named SARS-CoV-2 virus), was fistly reported in Wuhan, Hubei Province, China towards the end of 2019. Large-scale spread within China and internationally led the World Health Organization to declare a Public Health Emergency of International Concern on 30(th) January 2020. The clinical manifestations of COVID-19 virus infection include asymptomatic infection, mild upper respiratory symptoms, severe viral pneumonia with respiratory failure, and even death. There are no antivirals of proven clinical efficacy in coronavirus infections. Remdesivir (GS-5734), a nucleoside analogue, has inhibitory effects on animal and human highly pathogenic coronaviruses, including MERS-CoV and SARS-CoV, in in vitro and in vivo experiments. It is also inhibitory against the COVID-19 virus in vitro. The aim of this study is to assess the efficacy and safety of remdesivir in adult patients with severe COVID-19. METHODS: The protocol is prepared in accordance with the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) guidelines. This is a phase 3, randomized, double-blind, placebo-controlled, multicentre trial. Adults (>/= 18 years) with laboratory-confirmed COVID-19 virus infection, severe pneumonia signs or symptoms, and radiologically confirmed severe pneumonia are randomly assigned in a 2:1 ratio to intravenously administered remdesivir or placebo for 10 days. The primary endpoint is time to clinical improvement (censored at day 28), defined as the time (in days) from randomization of study treatment (remdesivir or placebo) until a decline of two categories on a six-category ordinal scale of clinical status (1 = discharged; 6 = death) or live discharge from hospital. One interim analysis for efficacy and futility will be conducted once half of the total number of events required has been observed. DISCUSSION: This is the first randomized, placebo-controlled trial in COVID-19. Enrolment began in sites in Wuhan, Hubei Province, China on 6(th) February 2020. TRIAL REGISTRATION: ClinicalTrials.gov: NCT04257656. Registered on 6 February 2020."],"journal":"Trials","authors":["Wang, Yeming","Zhou, Fei","Zhang, Dingyu","Zhao, Jianping","Du, Ronghui","Hu, Yi","Cheng, Zhenshun","Gao, Ling","Jin, Yang","Luo, Guangwei","Fu, Shouzhi","Lu, Qiaofa","Du, Guanhua","Wang, Ke","Lu, Yang","Fan, Guohui","Zhang, Yi","Liu, Ying","Ruan, Shunan","Liu, Wen","Jaki, Thomas","Hayden, Frederick G","Horby, Peter W","Cao, Bin","Wang, Chen"],"date":"2020-05-26T11:00:00Z","year":2020,"_id":"32448345","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1186/s13063-020-04352-9","keywords":["administrative information","antiviral","covid-19","china","clinical trial","remdesivir"],"locations":["Wuhan","Hubei","China","China","Wuhan","Hubei","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["remdesivir","Nucleosides"],"topics":["Treatment"],"weight":1,"_version_":1667785213936140289,"score":43.148373}]}